Tricida (TCDA) Reports In-Line Q3 EPS

Tricida (NASDAQ: TCDA) reported Q3 EPS of ($0.89), in-line with the analyst estimate of ($0.89).

“We are pleased that our application for veverimer was accepted for review under the Accelerated Approval Program and look forward to engaging with experts at an advisory committee meeting,” said Gerrit Klaerner, Ph.D., Tricida’s chief executive officer and president. “With a potential approval in August 2020, veverimer would be the first and only FDA-approved therapy for the chronic treatment of metabolic acidosis in patients with CKD. Our commercial team is targeting a successful launch with a full quarter of revenue in the fourth quarter of 2020.”

For earnings history and earnings-related data on Tricida (TCDA) click here.

You May Also Be Interested In

• Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
• AptarGroup (ATR) Tops Q1 EPS by 11c
• SPS Commerce (SPSC) Tops Q1 EPS by 12c